MIR4728: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

MIR4728: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, and can even lead to depression and anxiety. The development of new treatments for chronic pain is crucial for improving the lives of patients. In this article, we discuss MIR4728, a potential drug target and biomarker for the treatment of chronic pain.

MIR4728: A Potential Drug Target

MIR4728 is a small non-coding RNA (ncRNA) that has been shown to play a role in the development and progression of chronic pain. MIR4728 has been shown to regulate the activity of several pain-related genes, including TrkA, TrkB, and TrkC, which encode for neurotransmitters involved in pain signaling.

The MIR4728-TrkA interaction

MIR4728 has been shown to physically interact with TrkA, a key gene involved in pain signaling. MIR4728 has been shown to bind to TrkA using the G protein-coupled receptor (GPCR) domain, which is responsible for transmitting signals from the cell surface to intracellular targets. This interaction between MIR4728 and TrkA has been shown to play a role in the development of chronic pain.

MIR4728 has also been shown to regulate the activity of TrkB, another gene involved in pain signaling. TrkB is a GPCR that has been shown to play a role in the development of chronic pain. MIR4728 has been shown to physically interact with TrkB using the same GPCR domain, which is responsible for transmitting signals from the cell surface to intracellular targets.

MIR4728 has also been shown to regulate the activity of TrkC, another gene involved in pain signaling. TrkC is a GPCR that has been shown to play a role in the development of chronic pain. MIR4728 has been shown to physically interact with TrkC using the same GPCR domain, which is responsible for transmitting signals from the cell surface to intracellular targets.

MIR4728 as a biomarker

MIR4728 has also been shown to serve as a biomarker for the diagnosis and monitoring of chronic pain. The levels of MIR4728 have been shown to be elevated in individuals with chronic pain, and have been used as a target for drug development.

MIR4728 has been shown to be a potential drug candidate for the treatment of chronic pain due to its ability to regulate the activity of pain-related genes. The MIR4728-TrkA interaction has been shown to play a role in the development of chronic pain, and MIR4728 has been shown to be able to modulate the activity of TrkA, TrkB, and TrkC, which encode for neurotransmitters involved in pain signaling.

Conclusion

Chronic pain is a significant public health issue that can have a significant impact on an individual's quality of life. The development of new treatments for chronic pain is crucial for improving the lives of patients. MIR4728, a small non-coding RNA that has been shown to play a role in the development and progression of chronic pain, has the potential to be a new drug target and biomarker for the treatment of chronic pain. Further research is needed to fully understand the role of MIR4728 in the treatment of chronic pain and to develop safe and effective treatments.

Protein Name: MicroRNA 4728

The "MIR4728 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4728 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000 | MIR5001 | MIR5002 | MIR5003 | MIR5004